Sets Cannabis Testing Market Trends

Growth Drivers

• Rising legalization of therapeutic and recreational use of cannabis - Many nations have legalized cannabis usage for medical purposes as well as recreational drugs and adult use in the past few years. This is explained by the recently recognized medicinal potential of cannabis and items infused with it. Research has demonstrated that cannabis can offer significant relief from side effects, including nausea brought on by chemotherapy and multiple sclerosis-related chronic pain.
  
  The World Drug Report 2022 from the UN Office on Drugs and Crime (UNODC) states that 284 million individuals between the ages of 15 and 64 took drugs globally in 2020, a 26% rise over the preceding ten years. Drug usage among youth has increased; in many nations, current drug use rates are greater than those of earlier generations.
• Initiation of new medical testing technologies - The public can benefit from improved healthcare accessibility and flexibility through the use of digital medical technologies. It includes publicly available data about health, medical conditions, treatments, side effects, and current advancements in biomedical research. These days, medical and diagnostic services are become easier to get, especially in low-income nations.
  
  For instance, Abbot Laboratories alone invested over 3 billion dollars in research and development in 2023. Moreover, cannabis testing is the process of analyzing a single sample of cannabis to find out its levels of THC, CBD, and terpenes as well as any pollutants or impurities like bugs, mildew, illness, residual solvents, or pesticide residue. These technological advancements helping in the huge implementation of cannabis testing.
• The growing LIMS use in cannabis testing facilities - Since many states have legalized cannabis for recreational and medicinal purposes in adults, thorough and trustworthy analytical testing is required to guarantee product potency and customer safety. To address this void, an increasing number of laboratories focused on testing cannabis and cannabis-derived products are springing up.

Challenges

• Fluctuation in therapeutic standardization of cannabis - The debate surrounding the therapeutic efficacy of cannabis remains unresolved, despite widespread support for the safety of currently available cannabis products. Several participants have noted that the classification of cannabis as a Schedule I drug in the US impedes research efforts regarding this important issue.
• Lack of research on the use of cannabis - There has been little study conducted in the US on the health consequences of cannabis and cannabinoids, which prevents individuals, medical professionals, and policymakers from having access to the information they need to make informed decisions about using cannabis and cannabinoids. There is a risk to public health since there is a dearth of evidence-based knowledge on how cannabis and cannabinoids affect health.